TherapeuticsMD (TXMD) Stock Rating Upgraded by Zacks Investment Research

TherapeuticsMD (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Saturday.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

Several other equities research analysts have also recently commented on the company. BidaskClub raised TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 25th. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, November 30th. Cowen reissued an “outperform” rating and issued a $16.00 target price (up from $13.00) on shares of TherapeuticsMD in a research note on Monday, November 6th. Cantor Fitzgerald reissued a “buy” rating and issued a $31.00 target price on shares of TherapeuticsMD in a research note on Wednesday, November 29th. Finally, Oppenheimer set a $10.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $14.50.

TherapeuticsMD (TXMD) traded up $0.13 during mid-day trading on Friday, reaching $6.30. The company had a trading volume of 2,562,847 shares, compared to its average volume of 2,430,000. TherapeuticsMD has a 12-month low of $3.50 and a 12-month high of $8.30. The firm has a market cap of $1,390.00, a PE ratio of -16.15 and a beta of 1.06.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The company had revenue of $4.42 million during the quarter, compared to analysts’ expectations of $5.36 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business’s revenue for the quarter was down 19.7% on a year-over-year basis. During the same period last year, the firm earned ($0.13) EPS. equities analysts expect that TherapeuticsMD will post -0.37 earnings per share for the current year.

In related news, Director Tommy G. Thompson purchased 5,000 shares of TherapeuticsMD stock in a transaction dated Friday, December 8th. The shares were acquired at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the transaction, the director now directly owns 3,555 shares of the company’s stock, valued at $22,076.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 23.92% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of TXMD. Schwab Charles Investment Management Inc. boosted its position in shares of TherapeuticsMD by 10.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after purchasing an additional 67,855 shares during the last quarter. Rhumbline Advisers boosted its position in shares of TherapeuticsMD by 3.5% in the 2nd quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock worth $967,000 after purchasing an additional 6,232 shares during the last quarter. Legal & General Group Plc boosted its position in shares of TherapeuticsMD by 6.5% in the 2nd quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock worth $298,000 after purchasing an additional 3,441 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of TherapeuticsMD by 3.9% in the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of TherapeuticsMD by 10.8% in the 2nd quarter. Alliancebernstein L.P. now owns 254,240 shares of the company’s stock worth $1,340,000 after purchasing an additional 24,700 shares during the last quarter. Institutional investors and hedge funds own 73.69% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/20/therapeuticsmd-txmd-stock-rating-upgraded-by-zacks-investment-research.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply